Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
New study presents a human-relevant stress model for assessing potential therapeutics
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The platform is being introduced to expand access to treatments for people living with chronic conditions
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Subscribe To Our Newsletter & Stay Updated
